A landmark UTI drug approval, new hope for the amyloid hypothesis in Alzheimer’s disease, a brewing vaccine study controversy, and more led the news this week.
Mixed messages surrounding their clinical benefits threatened the legitimacy of stem cell therapies for multiple sclerosis, but there is still plenty of promise.